• Phase 3 osteoarthritis trial completed final patient visits, results expected in Q2 2026
• Phase 2 aGvHD trial completed patient enrolment, results expected in June 2026
• Phase 1/2 kidney transplantation trial progressing with second cohort after positive DSMB review

Cynata Therapeutics Limited reported a loss of $2,662,437 for the half-year ended 31 December 2025, compared to a loss of $3,649,792 in the prior corresponding period. The company received a $1.71 million R&D tax incentive rebate during the half-year. As at 31 December 2025, Cynata had $2.6 million in cash, with a further $1.2 million raised subsequently via an ATM facility, extending the company's cash runway into mid-2026.Key highlights during the half-year included:- Completion of final patient visits in the Phase 3 osteoarthritis trial, with results expected in Q2 2026- Completion of patient enrolment in the Phase 2 acute graft-versus-host disease (aGvHD) trial, with results anticipated around June 2026- Progression of the Phase 1/2 kidney transplantation trial to the second cohort following a positive independent DSMB review of the first cohortCynata continues to strengthen its intellectual property portfolio, with several patent allowances and grants across the US and Europe. The company remains focused on disciplined capital management to support upcoming milestones, including the reporting of results from its Phase 3 osteoarthritis and Phase 2 aGvHD trials in Q2 2026.

Cynata is entering a period focused on the analysis and reporting of clinical data from its leading programs, with two major efficacy trials nearing completion. The company expects to report results from both its Phase 3 osteoarthritis trial and Phase 2 aGvHD trials in Q2 2026, which will inform the next stage of development and strategic decision-making. Alongside these readouts, Cynata will continue active engagement with regulatory authorities to clarify potential approval pathways and development requirements. The company is also preparing for next-stage clinical and commercial planning across its pipeline, including evaluation of partnering, licensing and regional development opportunities where appropriate.